Abstract: Contiguity information is important to achieving high-quality de novo assembly of mammalian genomes and the haplotype-resolved resequencing of human genomes. The methods described herein pursue cost-effective, massively parallel capture of contiguity information at different scales.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
April 12, 2022
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jay Ashok Shendure, Jerrod Joseph Schwartz, Andrew Colin Adey, Cho li Lee, Joseph Brian Hiatt, Jacob Otto Kitzman, Akash Kumar
Abstract: The present disclosure provides encoded chromophoric polymer particles that are capable of, for example, optical and/or biomolecular encoding of analytes. The present disclosure also provides suspensions comprising a plurality of encoded chromophoric polymer particles. The present disclosure also provides methods of using the encoded chromophoric polymer particles and systems for performing multiplex analysis with encoded chromophoric polymer particles.
Type:
Application
Filed:
November 30, 2021
Publication date:
March 17, 2022
Applicant:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Daniel T. Chiu, Changfeng Wu, Jiangbo Yu
Abstract: Compositions and methods for the treatment of toxoplasmosis, caused by the infectious eukaryotic parasite Toxoplasma gondii (T. gondii) and for the treatment of cryptosporidiosis, caused by the infectious eukaryotic parasites Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus) are described. In particular, the present disclosure is directed to compositions and methods for inhibiting either T. gondii calcium dependent protein kinases (TgCDPKs) or C. parvum and C. hominus calcium dependent protein kinases (CpCDPKs) using pyrazolopyrimidine and/or imidazo[1,5-a]pyrazine inhibitors, of the formula, wherein the variables X, Y, Z, L, R1, and R3 are defined herein.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
February 15, 2022
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Wesley C. Van Voorhis, Wilhelmus G. J. Hol, Eric T. Larson, Dustin James Maly, Ethan Merritt, Kayode K. Ojo
Abstract: The present invention provides recombinant adenoviral compositions and methods for their use in treating disorders associated with epithelial tissues.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
February 15, 2022
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
Type:
Application
Filed:
October 20, 2021
Publication date:
February 10, 2022
Applicant:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Mary L. DISIS, Denise Cecil, Meredith Slota
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
February 8, 2022
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: The present disclosure provides encoded chromophoric polymer particles that are capable of, for example, optical and/or biomolecular encoding of analytes. The present disclosure also provides suspensions comprising a plurality of encoded chromophoric polymer particles. The present disclosure also provides methods of using the encoded chromophoric polymer particles and systems for performing multiplex analysis with encoded chromophoric polymer particles.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
January 11, 2022
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Daniel T. Chiu, Changfeng Wu, Jiangbo Yu
Abstract: This invention relates to a process for producing lipids and amino acids from a gaseous substrate comprising methane and oxygen. The process uses a culture of a methanotrophic microorganism in a liquid nutrient medium. The methanotrophic microorganism can be a Methylomicrobium bacterium and more specifically Methylomicrobium buryatense 5GB1. The lipid products can be in the cellular membrane of the methanotroph and can be extracted in a separate extraction zone.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
January 11, 2022
Assignees:
LanzaTech New Zealand Limited, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, ALLIANCE FOR SUSTAINABLE ENERGY, LLC
Inventors:
Mary Elizabeth Lidstrom, Marina Georgievna Kalyuzhnaya, Derek Wayne Griffin, Nicholas Bourdakos, Philip Thomas Pienkos, Lieve Maria Louisa Laurens
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
December 14, 2021
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
Type:
Grant
Filed:
June 25, 2021
Date of Patent:
November 30, 2021
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Mary L. Disis, Denise Cecil, Meredith Slota
Abstract: An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more FcyR1-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more FcRn-binding domains.
Type:
Grant
Filed:
February 11, 2015
Date of Patent:
November 30, 2021
Assignees:
Albany Medical College, University of Washington through its Center for Commercialization
Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
Type:
Application
Filed:
June 25, 2021
Publication date:
November 11, 2021
Applicant:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Mary L. DISIS, Denise CECIL, Meredith SLOTA
Abstract: The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
November 9, 2021
Assignees:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
George Pavlakis, Barbara Felber, James Mullins
Abstract: An adaptive system for efficient and long-range wireless power delivery using magnetically coupled resonators responds to changes in a dynamic environment, and maintains high efficiency over a narrow or fixed frequency range. The system uses adaptive impedance matching to maintain high efficiency. The wireless power transfer system includes a drive inductor coupled to a high-Q transmitter coil, and a load inductor coupled to a high-Q receiver coil. The transmitter coil and receiver coil for a magnetically coupled resonator. A first matching network is (i) operably coupled to the drive inductor and configured to selectively adjust the impedance between the drive inductor and the transmitter coil, or (ii) is operably coupled to the load inductor and configured to selectively adjust the impedance between the load inductor and the receiver coil.
Type:
Application
Filed:
July 15, 2021
Publication date:
November 4, 2021
Applicant:
University of Washington through its Center for Commercialization
Inventors:
Joshua R. Smith, Benjamin H. Waters, Scott Wisdom, Alanson P. Sample
Abstract: Methods are provided for detecting enzymatic activity of various lysosomal storage enzymes using substrates that include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which is sufficiently structured to provide improved solubility in aqueous or organic solvent systems. Also provided are internal standards, and inhibitors for use in detecting or reducing enzymatic activity using the inventive substrates.
Type:
Grant
Filed:
June 21, 2016
Date of Patent:
October 26, 2021
Assignees:
University of Washington through its Center for Commercialization, PerkinElmer Health Sciences, Inc.
Inventors:
Alexander Cherkassky, Jason Coumoyer, Michael Gelb
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
October 26, 2021
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
September 28, 2021
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 31, 2020
Date of Patent:
September 14, 2021
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt